493 related articles for article (PubMed ID: 20578268)
1. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.
Musso G; Gambino R; Cassader M; Pagano G
Hepatology; 2010 Jul; 52(1):79-104. PubMed ID: 20578268
[TBL] [Abstract][Full Text] [Related]
2. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.
Musso G; Cassader M; Rosina F; Gambino R
Diabetologia; 2012 Apr; 55(4):885-904. PubMed ID: 22278337
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Musso G; Cassader M; Paschetta E; Gambino R
JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
[TBL] [Abstract][Full Text] [Related]
4. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
5. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
[TBL] [Abstract][Full Text] [Related]
6. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.
Mahady SE; Webster AC; Walker S; Sanyal A; George J
J Hepatol; 2011 Dec; 55(6):1383-90. PubMed ID: 21703200
[TBL] [Abstract][Full Text] [Related]
7. Vitamin E and nonalcoholic fatty liver disease.
Pacana T; Sanyal AJ
Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
[TBL] [Abstract][Full Text] [Related]
8. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?
Musso G; Anty R; Petta S
Curr Pharm Des; 2013; 19(29):5297-313. PubMed ID: 23394094
[TBL] [Abstract][Full Text] [Related]
9. Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review.
Mann JP; Tang GY; Nobili V; Armstrong MJ
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1457-1476.e7. PubMed ID: 29857146
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
[TBL] [Abstract][Full Text] [Related]
11. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
Tilg H; Moschen A
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):159-67. PubMed ID: 20485253
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials.
He L; Liu X; Wang L; Yang Z
Medicine (Baltimore); 2016 Oct; 95(42):e4947. PubMed ID: 27759627
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease from pathogenesis to management: an update.
Musso G; Gambino R; Cassader M
Obes Rev; 2010 Jun; 11(6):430-45. PubMed ID: 19845871
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.
Nseir W; Mograbi J; Ghali M
Dig Dis Sci; 2012 Jul; 57(7):1773-81. PubMed ID: 22419057
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
[TBL] [Abstract][Full Text] [Related]
16. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.
Musso G; Gambino R; Cassader M; Pagano G
Ann Med; 2011 Dec; 43(8):617-49. PubMed ID: 21039302
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
[TBL] [Abstract][Full Text] [Related]
19. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S
Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
[TBL] [Abstract][Full Text] [Related]
20. Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
Riche DM; Fleming JW; Malinowski SS; Black CA; Miller KH; Wofford MR
Ann Pharmacother; 2014 Jan; 48(1):137-41. PubMed ID: 24259612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
